A new trading day began on Tuesday, with Black Diamond Therapeutics Inc (NASDAQ: BDTX) stock price up 9.69% from the previous day of trading, before settling in for the closing price of $2.27. BDTX’s price has ranged from $1.20 to $6.75 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -5.22% over the past five years. Meanwhile, its annual earnings per share averaged 119.16%. With a float of $43.30 million, this company’s outstanding shares have now reached $56.68 million.
Let’s look at the performance matrix of the company that is accounted for 24 employees. In terms of profitability, gross margin is 99.75%, operating margin of -5.72%, and the pretax margin is 7.27%.
Black Diamond Therapeutics Inc (BDTX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Black Diamond Therapeutics Inc is 23.86%, while institutional ownership is 62.07%. The most recent insider transaction that took place on Mar 19 ’25, was worth 11,997,749. In this transaction 10% Owner of this company sold 5,784,292 shares at a rate of $2.07, taking the stock ownership to the 2,733,547 shares. Before that another transaction happened on Aug 28 ’24, when Company’s 10% Owner sold 221,600 for $6.32, making the entire transaction worth $1,400,556. This insider now owns 3,726,341 shares in total.
Black Diamond Therapeutics Inc (BDTX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 119.16% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.33% during the next five years compared to -5.22% drop over the previous five years of trading.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Trading Performance Indicators
Here are Black Diamond Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 9.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.06, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -1.02 in one year’s time.
Technical Analysis of Black Diamond Therapeutics Inc (BDTX)
Black Diamond Therapeutics Inc (NASDAQ: BDTX) saw its 5-day average volume 0.87 million, a negative change from its year-to-date volume of 2.27 million. As of the previous 9 days, the stock’s Stochastic %D was 49.82%.
During the past 100 days, Black Diamond Therapeutics Inc’s (BDTX) raw stochastic average was set at 79.63%, which indicates a significant increase from 62.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.11% in the past 14 days, which was lower than the 79.44% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.96, while its 200-day Moving Average is $2.55. Nevertheless, the first resistance level for the watch stands at $2.57 in the near term. At $2.65, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.79. If the price goes on to break the first support level at $2.34, it is likely to go to the next support level at $2.20. The third support level lies at $2.12 if the price breaches the second support level.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Key Stats
With a market capitalization of 141.59 million, the company has a total of 56,863K Shares Outstanding. Currently, annual sales are 0 K while annual income is -69,680 K. The company’s previous quarter sales were 70,000 K while its latest quarter income was 56,540 K.
